Scott T. Rottinghaus, M.D., currently holds the position of Chief Medical Officer at Enanta Pharmaceuticals Inc., a biotechnology company focused on developing novel small molecule drugs for the treatment of viral infections and liver diseases. Dr. Rottinghaus brings a wealth of experience to his role, having spent over two decades in the pharmaceutical industry. Prior to joining Enanta, he served as Senior Vice President and Head of Clinical Development at BioCryst Pharmaceuticals, where he was instrumental in advancing multiple drug candidates through clinical trials, including the approval of ORLADEYO® for the prevention of hereditary angioedema attacks. Dr. Rottinghaus's career is marked by significant achievements in drug development and clinical research. He has been involved in the development of several successful drugs across various therapeutic areas, including infectious diseases, hematology, and oncology. His expertise in designing and executing clinical trials has been crucial in bringing innovative treatments to patients. At Enanta, Dr. Rottinghaus leads the clinical development strategy for the company's pipeline, which includes promising candidates for the treatment of respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH). As Chief Medical Officer, Dr. Rottinghaus plays a pivotal role in guiding Enanta's research and development efforts. He collaborates closely with cross-functional teams to ensure that the company's clinical programs are executed efficiently and meet regulatory standards. His leadership and strategic vision are key to advancing Enanta's mission of delivering transformative therapies to patients with high unmet medical needs. Dr. Rottinghaus's dedication to improving patient outcomes and his extensive industry experience make him a valuable asset to Enanta Pharmaceuticals Inc.